IDP Pharma and BCN Peptides engage in the development of a new chemical entity aimed to treat Multiple Myeloma. The collaborative project has been granted with funds from the European Union FEDER via ACCIO and its programme “Nuclis d’Innovació Tecnológica”.

IDP Pharma will attend next BIO-Europe spring, Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. It is regarded as a “must attend” event for the biotech industry. This event will take place in Barcelona from 20-22 March 2017.

IDP Pharma has closed a 1,4M€ seed investment round, following a pre-seed round of 0,1M€ (June 2015) , which adds to the 1,2M€ funds granted by several public institutions (MINECO, ENISA, CDTI-NEOTEC and ACCIÓ).

The company will allocate the capital to advance the preclinical development of its first products for two cancer indications, to set up new discovery programs, and to continue developing its technology: IDP-Platform.

IDP Pharma will attend next Bio International Convention 2016 in San Francisco, the world’s largest biotechnology event. The BIO attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. You will find partnering opportunities, an outstanding education program, an expansive exhibition floor, and exclusive networking events where you will access over 2,500 CEO’s from leading biotech companies.

IDP Pharma has closed its first investment round. The funds raised will allow the company to develop its technology and deliver first active compounds against an IDP, a novel class of therapeutic targets.

IDP Pharma has stablished its headquarters at the Parc Científic de Barcelona (PCB).

The Parc Científic de Barcelona offers institutions and companies an ideal environment dedicated to the generation, transfer and addition of value in the field of the life sciences, with state-of-the-art facilities for drug discovery.